Implementation
Objective Overview
According to FORTUNE, an American Business magazine, the global diabetes treatment
market size was estimated to be approximately $48753.1 million in 2018, which is projected to reach $78261.7 Million
by the end of 2026. Such a promising market means a lot of demand and also means that many people with diabetes are
waiting for help.To solve the problem of the continuously increasing number of diabetes patients. Our De-Dia team
find a compound that will activate glucosekineas which command the pancreas to produce insulin and lower blood
sugar.
Target Users
The high incidence of diabetes has been a problem that has plagued us for many years.
Especially nowadays, the number of diabetes patients is increasing dramatically. To relieve the stress brought by
the disease, our team proposed the idea of the activation of glucosekineas.
1. Type 2 diabetes patients
The method which activates glucosekineas is not commonly available in the markets which
makes our products
unique. Our medicine has a reasonable and relatively affordable price for most patients so that more and more
patients could relieve their illnesses with the use of our product. By using our product, there is fewer side
effect, and situation such as hypoglycemia will not occur. With the advantages in effectiveness and price, our
products are very competitive.
2. Hospitals and medical institutions
Hospitals and medical institutions could purchase batches of our product, we could offer
them lower prices.
Our business aim to replace the traditional method of treatment for diabetes, and at the same time provide the patient’s a more effective treatment; nevertheless, once the hospitals and medical institutions purchase our product and apply it in operations or sell them directly to patients, more and more patients would be healthier and have a brighter future.
Our business aim to replace the traditional method of treatment for diabetes, and at the same time provide the patient’s a more effective treatment; nevertheless, once the hospitals and medical institutions purchase our product and apply it in operations or sell them directly to patients, more and more patients would be healthier and have a brighter future.
Product
Our products are compounds used to treat patients with type 2 diabetes. But our products
are different from most
of the products on the market. At present, the known drugs for the treatment of diabetes in the market are usually
injected with insulin directly. But this method will cause great harm to the patients themselves. The patient may
change from hyperglycemia to hypoglycemia, and the injection site of the patient may have fat liquefaction and red
surface. These phenomena will also lead to incomplete absorption of insulin. But our products are relatively mild.
Our compound directly activates GK (glucokinase) in the body. Then GK (glucokinase) will mobilize the body's
hypoglycemic mechanism. And patients are not easy to cause side effects when using it.
Principle
So far, dozens of GK agonists have entered clinical trials, among which Dorzagliatin developed by Huoling
Pharmaceutical has entered the stage of drug registration and marketing in China, and is expected to become the
first GK small molecule agonist on the market. It has a significant hypoglycemic effect in phase 2 and phase 3
clinical studies, almost no adverse reaction of hypoglycemia, and can significantly improve the function of
pancreatic β cells, effectively maintaining the stability of blood glucose. Therefore, the development of novel
small molecule agonists targeting GK has a good application prospect. The principle of our product can be explained
as below:
Figure 1. Mechanism of GK regulating blood glucose balance
Step 1: Construct hGK2 prokaryotic expression plasmid
Step 2: Purify hGK2 protein
Step 3: Establish a screening platform for glucokinase agonists
Step 4: Detect the effect of active compounds on glucose-stimulating insulin secretion role of cells
Step 2: Purify hGK2 protein
Step 3: Establish a screening platform for glucokinase agonists
Step 4: Detect the effect of active compounds on glucose-stimulating insulin secretion role of cells
Safety and Challenges
In the stage of product development in the laboratory, we will strictly follow the
relevant regulations and ensure safety throughout the whole experiment. Escherichia coli M15 and Ins-832/13 were
used in the study which was non-toxic and non-pathogenic, all experiments were carried out on a sterile experimental
bench without external contamination. all of the apparatuses, such as Petri dishes, beakers, and measuring
cylinders, are cleaned or sterilized before use. All wasted liquid from culturing cells has been properly disposed
of and all medical wastes generated in experiments are stored in designated areas, which minimizes the risk of
biohazardous substances in the laboratory polluting the environment.
In regard to our product, ass a brand-new Biotechnological product, there will be two main problems that we will take into account. first, we don't know the potential threat and side effects of our product. For example, if some people have other pathology which will cause them danger after taking our product. Secondly, there might be some risk of conflict with other drugs.
There are some future challenges that our business would face in the future. For example, as a new firm, we still need further experiments samples and data collected from our customers. Then, because our medicine is newly released in the market, some people doubt the safety of our medicine. So, chances are they will not purchase our product, which would take a toll on our income. Last but not least, as a medicine, we are bound to have a challenge of drug resistance.
In regard to our product, ass a brand-new Biotechnological product, there will be two main problems that we will take into account. first, we don't know the potential threat and side effects of our product. For example, if some people have other pathology which will cause them danger after taking our product. Secondly, there might be some risk of conflict with other drugs.
There are some future challenges that our business would face in the future. For example, as a new firm, we still need further experiments samples and data collected from our customers. Then, because our medicine is newly released in the market, some people doubt the safety of our medicine. So, chances are they will not purchase our product, which would take a toll on our income. Last but not least, as a medicine, we are bound to have a challenge of drug resistance.
Future Plan
We hope to optimize the experiment and get more reliable data to rule out side effects
through various tests. In
addition, we understand there will be a long way for us to pass the clinical trials, and we will cooperate with
other medical companies or relative research groups to continue the development work and finally commercialize our
products.
Regarding our promotion strategy, we will release news on major websites (Tiktok, Bili Bili, Weibo, etc.). Put the characteristics of our compounds in the news, let the pharmaceutical companies know and understand our products, and update the progress of our compounds. We have drafted our business plan where we settle down the future business in detail.
Regarding our promotion strategy, we will release news on major websites (Tiktok, Bili Bili, Weibo, etc.). Put the characteristics of our compounds in the news, let the pharmaceutical companies know and understand our products, and update the progress of our compounds. We have drafted our business plan where we settle down the future business in detail.
Reference:
1. Al-Hasani, H., Tschöp, M. H., & Cushman, S. W. (2003). Two birds with one stone:
novel glucokinase activator stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose
metabolism. Molecular interventions, 3(7), 367.